Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

539 ARTÍCULOS , VIENDO DEL 406 AL 420

Two-level diagnostic classification using cerebrospinal fluid YKL-40 in Alzheimer's disease

Baldacci F, Toschi N, Lista S, Zetterberg H, Blennow K, Kilimann I, Teipel S, Cavedo E, Dos Santos AM, Epelbaum S, Lamari F, Dubois B, Floris R, Garaci F, Bonuccelli U, Hampel H.

Alzheimers Dement. 2017 Sep;13(9):993-1003. doi: 10.1016/j.jalz.2017.01.021. Epub 2017 Mar 3.

Diagnostic function of the neuroinflammatory biomarker YKL-40 in Alzheimer's disease and other neurodegenerative diseases

Baldacci F, Lista S, Cavedo E, Bonuccelli U, Hampel H.

Expert Rev Proteomics. 2017 Apr;14(4):285-299. doi: 10.1080/14789450.2017.1304217. Epub 2017 Mar 20.

The biomarker-based diagnosis of Alzheimer's disease. 1-ethical and societal issues

Porteri C, Albanese E, Scerri C, Carrillo MC, Snyder HM, Martensson B, Baker M, Giacobini E, Boccardi M, Winblad B, Frisoni GB, Hurst S; Geneva Task Force for the Roadmap of Alzheimer's Biomarkers.

Neurobiol Aging. 2017 Apr;52:132-140. doi: 10.1016/j.neurobiolaging.2016.07.011.

Clinical validity of delayed recall tests as a gateway biomarker for Alzheimer's disease in the context of a structured 5-phase development framework

Cerami C, Dubois B, Boccardi M, Monsch AU, Demonet JF, Cappa SF; Geneva Task Force for the Roadmap of Alzheimer's Biomarkers.

Neurobiol Aging. 2017 Apr;52:153-166. doi: 10.1016/j.neurobiolaging.2016.03.034.

Clinical validity of medial temporal atrophy as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework

Ten Kate M, Barkhof F, Boccardi M, Visser PJ, Jack CR Jr, Lovblad KO, Frisoni GB, Scheltens P; Geneva Task Force for the Roadmap of Alzheimer's Biomarkers.

Neurobiol Aging. 2017 Apr;52:167-182.e1. doi: 10.1016/j.neurobiolaging.2016.05.024.

Clinical validity of brain fluorodeoxyglucose positron emission tomography as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework

Garibotto V, Herholz K, Boccardi M, Picco A, Varrone A, Nordberg A, Nobili F, Ratib O; Geneva Task Force for the Roadmap of Alzheimer's Biomarkers.

Neurobiol Aging. 2017 Apr;52:183-195. doi: 10.1016/j.neurobiolaging.2016.03.033.

Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework

Mattsson N, Lönneborg A, Boccardi M, Blennow K, Hansson O; Geneva Task Force for the Roadmap of Alzheimer's Biomarkers.

Neurobiol Aging. 2017 Apr;52:196-213. doi: 10.1016/j.neurobiolaging.2016.02.034.

Clinical validity of presynaptic dopaminergic imaging with (123)I-ioflupane and noradrenergic imaging with (123)I-MIBG in the differential diagnosis between Alzheimer's disease and dementia with Lewy bodies in the context of a structured 5-phase development framework

Sonni I, Ratib O, Boccardi M, Picco A, Herholz K, Nobili F, Varrone A; Geneva Task Force for the Roadmap of Alzheimer's Biomarkers.

Neurobiol Aging. 2017 Apr;52:228-242. doi: 10.1016/j.neurobiolaging.2016.04.026.

Multiplexing Biomarker Methods, Proteomics and Considerations for Alzheimer's Disease

Robinson RA, Amin B, Guest PC.

Adv Exp Med Biol. 2017;974:21-48. doi: 10.1007/978-3-319-52479-5_2.

Early Detection of Learning Difficulties when Confronted with Novel Information in Preclinical Alzheimer's Disease Stage 1

Tort-Merino A, Valech N, Peñaloza C, Grönholm-Nyman P, León M, Olives J, Estanga A, Ecay-Torres M, Fortea J, Martínez-Lage P, Molinuevo JL, Laine M, Rodríguez-Fornells A, Rami L.

J Alzheimers Dis. 2017;58(3):855-870. doi: 10.3233/JAD-161173.

Biochemical markers in vascular cognitive impairment associated with subcortical small vessel disease - A consensus report

Wallin A, Kapaki E, Boban M, Engelborghs S, Hermann DM, Huisa B, Jonsson M, Kramberger MG, Lossi L, Malojcic B, Mehrabian S, Merighi A, Mukaetova-Ladinska EB, Paraskevas GP, Popescu BO, Ravid R, Traykov L, Tsivgoulis G, Weinstein G, Korczyn A, Bjerke M, Rosenberg G.

BMC Neurol. 2017 May 23;17(1):102. doi: 10.1186/s12883-017-0877-3.

[Elucidating Pathogenic Mechanisms of Early-onset Alzheimer's Disease in Down Syndrome Patients]

Asai M, Kawakubo T, Mori R, Iwata N.

Yakugaku Zasshi. 2017;137(7):801-805. doi: 10.1248/yakushi.16-00236-2.

Relation of plasma selenium and lipid peroxidation end products in patients with Alzheimer's disease

Chmatalova Z, Vyhnalek M, Laczo J, Hort J, Pospisilova R, Pechova M, Skoumalova A.

Physiol Res. 2017 Dec 20;66(6):1049-1056. doi: 10.33549/physiolres.933601. Epub 2017 Sep 22.

Memory Correlates of Alzheimer's Disease Cerebrospinal Fluid Markers: A Longitudinal Cohort Study

Reijs BLR, Ramakers IHGB, Köhler S, Teunissen CE, Koel-Simmelink M, Nathan PJ, Tsolaki M, Wahlund LO, Waldemar G, Hausner L, Vandenberghe R, Johannsen P, Blackwell A, Vanderstichele H, Verhey F, Visser PJ.

J Alzheimers Dis. 2017;60(3):1119-1128. doi: 10.3233/JAD-160766.

Searching for new pharmacological targets for the treatment of Alzheimer's disease in Down syndrome

Caraci F, Iulita MF, Pentz R, Flores Aguilar L, Orciani C, Barone C, Romano C, Drago F, Cuello AC.

Eur J Pharmacol. 2017 Dec 15;817:7-19. doi: 10.1016/j.ejphar.2017.10.004. Epub 2017 Oct 5.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias